reason report
launch inheri biopharma inc
bottom line expect morn announc
launch inheri biopharma inc wholli own subsidiari
launch commerci nktr abuse-deterr opioid
inheri also take develop sever
opioid abus deterr product struggl gain foothold
amongst gener option remain skeptic
massiv commerci success model peak revenu
agre spin unit sensibl busi decis
given orthogon regulatori commerci market access
challeng pain vs oncolog
inheri prepar launch
pdufa date approach pdufa date set august
fda advisori committe adcom also expect schedul
august prepar approv complet
product launch inventori well market access prepar
distribut agreement plan technical-focus
commerci team heavi medic sale liaison
inheri manag experienc commerci
new presid ceo jay galeota previous held variou us
global leadership posit merck co led numer
brand product launch across varieti therapeut area
current mr galeota presid laboratori
continu look one potenti capit partner
support commerci launch launch inheri wholli
own subsidiari rais concern unabl
locat partner commerci possibl
follow fda approv potenti partner may amen
back wait determin option
viabl howev remain skeptic commerci viabil
assign model
inheri develop sever preclin asset
develop asset beyond increas scope
compani potenti beyond pain previous
disclos asset
dcf analysi simul revenu
royalti net cash sg
net debt total capit
price target use discount rate
compani given simul revenu stream
alreadi consid mani risk typic account
higher discount rate
year price history/av daili volume mil
compani inform svb leerink llc research
revenu ep
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
rx trend deriv im health
inheri like encount head wind commerci recal
previou analysi see slide contain within report recent opioid abus deterr
product struggl gain foothold believ sale may limit
label emphas risk abus deterr properti payer unwilling
pay premium price barrier system like impact well
pain asset current clinic review fda manag
emphas uniqu abus deterr technolog result dampen
like score delay pupil dilat approv believ inheri could use
revenu fund discoveri develop addit asset give
sum-of-the-part valuat peak sale base recent comp
embeda hysingla er xtampza er morphabond er arymo er roxybond targiniq er
market perform rate price target
believ likelihood failur bempeg higher typic given sub-
optim dose decis clinic de-risk non-registr
signal yet reach bar proof-of-concept poc
nktr/bmi develop strategi launch competit tumor set
multipl io therapi alreadi avail mani other pipelin
believ bempeg nivo level transform activ take
signific share option
posit side scale aggress parallel registr
program io-respons tumor type hedg risk partnership term deal
good increas price target pay major develop
cost bempeg nivo retain profit
earli pipelin see upsid valu pegyl agonist
bempeg program combin potenti colder tumor like triple-neg breast
cancer tnbc high risk success tumor offer upsid driver
valu model also believ pegyl overcom
bempeg challeng hedg risk back-up bempeg
sever import upcom catalyst especi august
octob time frame includ sarcoma updat melanoma data bempeg nivolumab
august advisori committe meet pdufa september/octob
expir joint clinic develop plan jcdp data bempeg
nivo tnbc cri-cimt-eati-aacr non-smal cell lung cancer nsclc esmo
novemb data bempeg nivo renal cell carcinoma rcc ikcc
project revenu deriv mont carlo simul rang
outcom part entir io industri pipelin valuat price target
base dcf analysi simul revenu bempeg plu
platform sale ylate product royalti take account net cash hand
 sg overhead cost
risk valuat
nsclc tnbc updat melanoma/rcc cohort posit meet
poc bar
bempeg nivo prove transform set better chemo
set high bar
tumor like melanoma rcc nsclc
recent opioid abus deterr product struggl gain foothold
competit market market access challeng
believ sale hamper
fda label emphas risk abus deterr properti
box warn languag like embeda expos user risk addict
abus misus lead overdos death assess patient
risk prescrib monitor regularli behavior condit
embeda formul sequest opioid antagonist naltrexon
hcl releas manipul crush buri label
payer unwilling pay premium price abus deterr patient combin
lack valid method select patient suscept addict
barrier system believ face challeng
ami fadia svb leerink pain high unmet need area pipelin still meager want fda guidanc fda iqvia
pegyl version oxycodon pre-clin
pre-clin data
bind mu-opioid receptor moder
rel low penetr compar
nhp habit format
compar opioid
clinic data patient treat
report reduct pre-
treatment pain score compar
poster annual frontier clinic investig symposium poster societi neurosci annual meet poster american
associ nurs practition nektar poster american societi anesthesiologist
delay dampen like score pupil diamet
believ abus deterr overdos protect
pegyl oxycodon design abus deterr altern due
pegyl reduc blood-brain barrier cross low high dose
delay dampen euphor respons compar oxycodon
physiochem properti stabil reveal known chemic
enzymat physic method hydrolyz deconjug otherwis produc known
abus opioid enabl rapid entri patient abus crush chew
tablet swallow
think fda may concern dampen impact stronger subject
mean like score object chang pupil diamet
face lot competit pain drug late stage
develop six abuse-deterr opioid
pain product current phase stage
ami fadia svb leerink pain high unmet need area pipelin still meager want fda guidanc biomedtrack
productindicationmechan actioncurr painsodium channel nsaidndaheronloteprednol pain and/or inflammationcorticosteroidndabausch health painnsaidndarecro back painopioidndanektaroxycodon erchron painopioidndaintellipharmaceuticsxaracollpostsurg painsodium channel ndainnocollampionosteoarthr painhuman serum painosteoclast inhibitoriiiaxsomebrixadichron back painopioidiiibraeburncebranopadolcanc painopioidiiigrnenthalcingalosteoarthr painviscosuppl pain clbpopioidiiiegaletfasinumaboa pain clbpngfiiiregeneron/tevahydexormoder sever painopioid acetaminophen antiemeticiiicharleston labsinvossaosteoarthr paingen therapi tissuegeneiv tramadolpostsurg painopioidiiiavenu therapeuticskorsuvapostsurg back painstem cell therapyiiimesoblastnerixiachron painbisphosphonateiiiabiogen pharmaoliceridineacut painopioidiiitrevenaoxycodon hcl iracut painopioidiiipmrsposidurpostsurg painsodium channel iiidurectremoxychron painopioidiiipain pain and/or inflammationcorticosteroidiiisparcsequestoxmoder sever painopioidiiielit paincorticosteroidiiisemnur pharmatanezumaboa pain clbpngfiiipfizer/lillyzalvisochron back painopioidiiiacelrx nektar
compet declin market feder agenc state legislatur
take step curb prescript opioid use
volum narcot analges dispens
rx opioid usag
mme
declin
notabl
mme
rx opioid usag increas pill per american adult
pill declin pill
ami fadia svb leerink pain high unmet need area pipelin still meager want fda guidanc iqvia medicin use spend
review outlook april
though fda encourag industri develop new opioid
gener version harder manipul
fda encourag develop new innov
drug abus deterr profil
fda also interest broaden use abuse-
fda issu guidanc requir abus
deterr label
guidanc industri abuse-deterr opioid
evalu label final guidanc explain
fda current think studi
conduct demonstr given formul
fda also look broaden use abuse-
deterr formul adf gener
current gener opioid fda-
fda guidanc develop gener abus
deterr gener oral solid opioid focus
tier-bas approach test base complex
difficulti effort releas opioid drug
evalu abus deterr specif
potenti rout abus
identifi effect manipul condit
test refer product prior
sampl select physic manipul
conduct compar vitro studi
compar test refer product extract
studi assess vulner product
statist comparison test refer product
guidanc essenti abuse-deterr opioid
approv
ami fadia svb leerink pain high unmet need area pipelin still meager want fda guidanc fda
except per share
clinic program overhead unalloc
